2025 Approvals

JOURNAVX(suzetrigine): FDA Approves  New Treatment for Acute Pain

JOURNAVX(suzetrigine): FDA Approves New Treatment for Acute Pain

What is it prescribed for? JOURNAVX is prescribed for the treatment of moderate to severe short-term (acute) pain in adults​. It was approved on January 30th 2025 What is the name of the drug and what does it do? The brand name is JOURNAVX (pronounced "JOR-na-vix"), and the generic name is suzetrigine. JOURNAVX is used to relieve acute pain that ranges from moderate...

DATROWAY: FDA Approves New Treatment for HR-Positive, HER2-Negative Breast Cancer

DATROWAY: FDA Approves New Treatment for HR-Positive, HER2-Negative Breast Cancer

What is it prescribed for? DATROWAY™ is used to treat adults with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have already received endocrine-based therapy and chemotherapy​. Datroway was Approved by the FDA on January 17 2025 What is the name of the drug and what does it do?...

IOMERVU: A New Radiographic Imaging Contrast Agent

IOMERVU: A New Radiographic Imaging Contrast Agent

IOMERVU is a newly approved radiographic contrast agent designed to enhance the visibility of blood vessels and organs during medical imaging procedures. It is used in both adults and children for intra-arterial and intravenous imaging, offering precise diagnostics for various medical conditions. IOMERVU was approved on November 27, 2024. What is the name of the...

Wegovy® Oral Tablet: A New Daily Pill Option for Weight Management

Wegovy® Oral Tablet: A New Daily Pill Option for Weight Management

Wegovy® has already changed how obesity is treated through a once-weekly injection. Now, Wegovy is entering a new phase. In early January 2026, Wegovy will become the first available daily oral GLP-1 tablet for chronic weight management, offering a pill option alongside the existing injectable form. This approval marks an important step for people who prefer an oral...